PLRX Stock Analysis: Buy, Sell, or Hold?
PLRX - Pliant Therapeutics, Inc. Common Stock
$1.16
0.03 (3.12%)
▲
5d:
+7.94%
30d:
+6.94%
90d:
-6.1%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When PLRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PLRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PLRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PLRX is currently trading at $1.16, which is considered extended relative to its 30-day fair value range of $1.04 to $1.12.
Technical Outlook: Technically, PLRX is in a strong downtrend. Immediate support is located at $1.02, while resistance sits at $1.23. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: PLRX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.50 (+123.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLRX is in a strong downtrend. Immediate support is located at $1.02, while resistance sits at $1.23. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: PLRX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.50 (+123.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.04 -
$1.12
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 123.2% below Wall St target ($2.50)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.04 -
$1.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.02
Resistance Level
$1.23
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.84
Wall Street Target
$2.50
(+123.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 23, 2026 10:56 AM ET
Data refreshes hourly during market hours. Next update: 11:56 AM
Data refreshes hourly during market hours. Next update: 11:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 38 SELL |
